首页> 外文期刊>Cancer Informatics >Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes
【24h】

Tumor RAS Gene Expression Levels Are Influenced by the Mutational Status of RAS Genes and Both Upstream and Downstream RAS Pathway Genes

机译:肿瘤RAS基因表达水平受RAS基因突变状态以及上游和下游RAS通路基因的突变状态的影响

获取原文
           

摘要

The 3 human RAS genes play pivotal roles regulating proliferation, differentiation, and survival in normal cells and become mutated in 15% to 20% of all human tumors and amplified in many others. In this report, we examined data from The Cancer Genome Atlas to investigate the relationship between RAS gene mutational status and messenger RNA expression. We show that all 3 RAS genes exhibit increased expression when they are mutated in a context-dependent manner. In the case of KRAS, this increase is manifested by a larger proportional increase in KRAS4A than KRAS4B, although both increase significantly. In addition, the mutational status of RAS genes can be associated with expression changes in other RAS genes, with most of these cases showing decreased expression. The mutational status associations with expression are recapitulated in cancer cell lines. Increases in expression are mediated by both copy number variation and contextual differences, including mutational status of epidermal growth factor receptor (EGFR) and BRAF. These findings potentially reveal an adaptive response during tumor evolution that is dependent on the mutational status of proximal genes in the RAS pathway and cellular context. Cell contextual differences in these adaptations may influence therapeutic responsiveness and alternative resistance mechanisms.
机译:这三种人类RAS基因在调节正常细胞的增殖,分化和存活中起关键作用,并在所有人类肿瘤的15%至20%中发生突变,并在许多其他肿瘤中扩增。在本报告中,我们检查了来自The Cancer Genome Atlas的数​​据,以研究RAS基因突变状态与Messenger RNA表达之间的关系。我们显示,当所有3种RAS基因以上下文依赖的方式突变时,它们都表现出增加的表达。在KRAS的情况下,尽管KRAS4A和KRAS4B均显着增加,但比例增加的幅度更大。此外,RAS基因的突变状态可能与其他RAS基因的表达变化有关,其中大多数情况下表达降低。在癌细胞系中概括了与表达的突变状态关联。表达的增加是由拷贝数变异和上下文差异介导的,包括表皮生长因子受体(EGFR)和BRAF的突变状态。这些发现潜在地揭示了在肿瘤进化过程中的适应性反应,其取决于RAS途径和细胞环境中近端基因的突变状态。这些适应中的细胞背景差异可能会影响治疗反应性和替代性耐药机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号